Quick Answer
Senti Biosciences Holdings, Inc. reported Diluted EPS of $2.73 per share (loss) for fiscal year 2025.
Senti Biosciences Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.73 | +77.3% |
| 2024 | -$12.03 | +24.9% |
| 2023 | -$16.01 | -617.9% |
| 2022 | -$2.23 | +88.3% |
| 2021 | -$19.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.69 | +89.1% | -23.2% |
| June 30, 2025 | -$0.56 | +77.1% | +60.3% |
| March 31, 2025 | -$1.41 | +46.8% | +77.7% |
| September 30, 2024 | -$6.31 | -87.8% | -157.6% |
| June 30, 2024 | -$2.45 | +41.9% | +7.5% |
| March 31, 2024 | -$2.65 | -531.0% | +21.1% |
| September 30, 2023 | -$3.36 | -784.2% | +20.4% |
| June 30, 2023 | -$4.22 | -390.7% | -904.8% |
- Senti Biosciences Holdings, Inc. showed an increase of +77.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Senti Biosciences Holdings, Inc.’s diluted eps has grown by 85.6% (from $19.00 per share (loss) to $2.73 per share (loss)).
- The most recent figure is from Senti Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: